286 related articles for article (PubMed ID: 11133854)
1. Improvement of lacrimal function by topical application of CyA in murine models of Sjögren's syndrome.
Tsubota K; Fujita H; Tadano K; Takeuchi T; Murakami T; Saito I; Hayashi Y
Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):101-10. PubMed ID: 11133854
[TBL] [Abstract][Full Text] [Related]
2. Use of topical cyclosporin A in a primary Sjögren's syndrome mouse model.
Tsubota K; Saito I; Ishimaru N; Hayashi Y
Invest Ophthalmol Vis Sci; 1998 Aug; 39(9):1551-9. PubMed ID: 9699544
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin Eye Drops Suppress Lacrimal Gland Inflammation In a Murine Model of Sjögren's Syndrome.
Shah M; Edman MC; Reddy Janga S; Yarber F; Meng Z; Klinngam W; Bushman J; Ma T; Liu S; Louie S; Mehta A; Ding C; MacKay JA; Hamm-Alvarez SF
Invest Ophthalmol Vis Sci; 2017 Jan; 58(1):372-385. PubMed ID: 28122086
[TBL] [Abstract][Full Text] [Related]
4. Amelioration of lacrimal gland inflammation by oral administration of K-13182 in Sjögren's syndrome model mice.
Nishiyama T; Mishima K; Obara K; Inoue H; Doi T; Kondo S; Saka M; Tabunoki Y; Hattori Y; Kodama T; Tsubota K; Saito I
Clin Exp Immunol; 2007 Sep; 149(3):586-95. PubMed ID: 17614971
[TBL] [Abstract][Full Text] [Related]
5. The role of Fas-Fas ligand-mediated apoptosis in autoimmune lacrimal gland disease in MRL/MpJ mice.
Jabs DA; Lee B; Whittum-Hudson J; Prendergast RA
Invest Ophthalmol Vis Sci; 2001 Feb; 42(2):399-401. PubMed ID: 11157873
[TBL] [Abstract][Full Text] [Related]
6. The role of fractalkine as an accelerating factor on the autoimmune exocrinopathy in mice.
Tsubota K; Nishiyama T; Mishima K; Inoue H; Doi T; Hattori Y; Kodama T; Higuchi A; Hayashi Y; Saito I
Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4753-60. PubMed ID: 19407023
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Cathepsin S Reduces Lacrimal Gland Inflammation and Increases Tear Flow in a Mouse Model of Sjögren's Syndrome.
Klinngam W; Janga SR; Lee C; Ju Y; Yarber F; Shah M; Guo H; Wang D; MacKay JA; Edman MC; Hamm-Alvarez SF
Sci Rep; 2019 Jul; 9(1):9559. PubMed ID: 31267034
[TBL] [Abstract][Full Text] [Related]
8. Mikulicz's disease and Sjögren's syndrome.
Tsubota K; Fujita H; Tsuzaka K; Takeuchi T
Invest Ophthalmol Vis Sci; 2000 Jun; 41(7):1666-73. PubMed ID: 10845583
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis and Sjögren syndrome.
Manganelli P; Fietta P
Semin Arthritis Rheum; 2003 Aug; 33(1):49-65. PubMed ID: 12920696
[TBL] [Abstract][Full Text] [Related]
10. The protein kinase C system in focal adenitis of the lacrimal gland in the non-obese diabetic mouse model for Sjögren's syndrome.
Tensing EK; Törnwall J; Hukkanen M; Nordström DC; Konttinen YT
Acta Ophthalmol Scand; 2004 Oct; 82(5):569-73. PubMed ID: 15453855
[TBL] [Abstract][Full Text] [Related]
11. The role of caspase cascade on the development of primary Sjögren's syndrome.
Hayashi Y; Arakaki R; Ishimaru N
J Med Invest; 2003 Feb; 50(1-2):32-8. PubMed ID: 12630566
[TBL] [Abstract][Full Text] [Related]
12. Inappropriate apoptosis of salivary and lacrimal gland epithelium of immunodeficient NOD-scid mice.
Kong L; Robinson CP; Peck AB; Vela-Roch N; Sakata KM; Dang H; Talal N; Humphreys-Beher MG
Clin Exp Rheumatol; 1998; 16(6):675-81. PubMed ID: 9844759
[TBL] [Abstract][Full Text] [Related]
13. Lymphocytic infiltration and goblet cell marker alteration in the conjunctiva of the MRL/MpJ-Fas(lpr) mouse model of Sjögren's syndrome.
Diebold Y; Chen LL; Tepavcevic V; Ferdman D; Hodges RR; Dartt DA
Exp Eye Res; 2007 Mar; 84(3):500-12. PubMed ID: 17208228
[TBL] [Abstract][Full Text] [Related]
14. Effective treatment of a mouse model of Sjögren's syndrome with eyedrop administration of anti-CD4 monoclonal antibody.
Hayashi Y; Ishimaru N; Arakaki R; Tsukumo S; Fukui H; Kishihara K; Shiota H; Yasutomo K; Hayashi Y
Arthritis Rheum; 2004 Sep; 50(9):2903-10. PubMed ID: 15457459
[TBL] [Abstract][Full Text] [Related]
15. Androgen influence on lacrimal gland apoptosis, necrosis, and lymphocytic infiltration.
Azzarolo AM; Wood RL; Mircheff AK; Richters A; Olsen E; Berkowitz M; Bachmann M; Huang ZM; Zolfagari R; Warren DW
Invest Ophthalmol Vis Sci; 1999 Mar; 40(3):592-602. PubMed ID: 10067962
[TBL] [Abstract][Full Text] [Related]
16. Comparative influence of steroid hormones and immunosuppressive agents on autoimmune expression in lacrimal glands of a female mouse model of Sjögren's syndrome.
Sato EH; Sullivan DA
Invest Ophthalmol Vis Sci; 1994 Apr; 35(5):2632-42. PubMed ID: 8163351
[TBL] [Abstract][Full Text] [Related]
17. Histologic examination of the NOD-mouse lacrimal glands, a potential model for idiopathic autoimmune dacryoadenitis in Sjogren's syndrome.
Moore PA; Bounous DI; Kaswan RL; Humphreys-Beher MG
Lab Anim Sci; 1996 Feb; 46(1):125-8. PubMed ID: 8699811
[No Abstract] [Full Text] [Related]
18. [A new treatment for reduced tear production].
Tiburtius H; Merker HJ
Klin Monbl Augenheilkd; 1973 Apr; 162(4):535-9. PubMed ID: 4724006
[No Abstract] [Full Text] [Related]
19. Lacrimal gland fluid secretion and lymphocytic infiltration in the NZB/W mouse model of Sjögren's syndrome.
Paranyuk Y; Claros N; Birzgalis A; Moore LC; Brink PR; Walcott B
Curr Eye Res; 2001 Sep; 23(3):199-205. PubMed ID: 11803482
[TBL] [Abstract][Full Text] [Related]
20. Lymphotoxin-beta receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of Sjögren's syndrome.
Fava RA; Kennedy SM; Wood SG; Bolstad AI; Bienkowska J; Papandile A; Kelly JA; Mavragani CP; Gatumu M; Skarstein K; Browning JL
Arthritis Res Ther; 2011; 13(6):R182. PubMed ID: 22044682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
